ADIA's Major Investment in Meril
In a significant move, the Abu Dhabi Investment Authority (ADIA), the UAE's largest sovereign wealth fund, has agreed to invest $200 million for a 3% stake in Meril (Micro Life Sciences), a leading medical devices company. This investment values Meril at an enterprise value of $6.6 billion, highlighting the company's strong market position and growth potential.

Regulatory Approval and Global Backing
The transaction is pending regulatory approval by the Competition Commission of India (CCI). Upon completion, Meril will be supported by two globally recognized investors: ADIA and Warburg Pincus, the latter having announced a $210 million investment for a minority stake in Meril in 2022.
Meril's Vision and Growth
Sanjeev Bhatt, senior vice president — strategy at Meril, expressed that this investment by ADIA underscores confidence in Meril's long-term vision and global ambitions. It will enable the company to accelerate growth, attract top talent, and enhance its R&D and clinical research efforts in advancing healthcare solutions.
About Meril
Founded by the Bilakhia Group, Meril specializes in clinically-advanced solutions across various specialties, including cardiovascular, structural heart, orthopedics, endo-surgery, in-vitro diagnostics, and surgical robotics. With its headquarters in Vapi, Gujarat, Meril boasts state-of-the-art, vertically integrated, and globally certified manufacturing and R&D facilities.
About ADIA
Established in 1976, ADIA is a globally diversified investment institution that manages funds on behalf of the Abu Dhabi government, focusing on long-term value creation.
Comments